About A public-private partnership that supports the discovery of new medicines through open access research. About SGC Partners Research Laboratories SGC-Toronto SGC-UNC SGC-Frankfurt SGC-Karolinska SGC-Neuro Governance Collaborators Open Science Equity, Diversity and Inclusion Impact Science and Resources Proteins Structure Gallery Expression Vectors Plasmids Constructs Production Protocols ChromoHub Phylogenetic Trees UbiHub Phylogenetic Trees ChemBioPort Chemical Probes Program CHEMICAL PROBES Donated chemical probes Chemical Handles Human Kinase Chemical Probe Program ANTIBODIES TARGET ENABLING PACKAGES (TEPs) TISSUE PLATFORM Open Lab Notebooks Open Chemistry Network PUBLICATIONS People Global Aled Edwards, CEO Susan McCormick, CFO Max Morgan, General Counsel and Public Policy Director SGC Toronto Cheryl Arrowsmith Dalia Barsyte-Lovejoy Takis Prinos Matthieu Schapira Levon Halabelian Rachel Harding SGC UNC Tim Willson Alison Axtman David Drewry Peter J. Brown Rafael M. Couñago SGC UCL Mat Todd SGC Karolinska Michael Sundström Opher Gileadi SGC Frankfurt Stefan Knapp Susanne Müller-Knapp Thomas Hanke Vladimir Rogov Krishnal Saxena Andreas Joerger Václav Němec Andreas Krämer Sandra Röhm SGC Neuro Edward Fon Thomas Durcan Jean-François Trempe Ziv Gan-Or Peter McPherson Carl Laflamme Roxanne Lariviere News & Outreach News & Events News from SGC Press Releases Events Blog Tweets by thesgconline Careers
A public-private partnership that supports the discovery of new medicines through open access research.
SGC0946 A potent, selective inhibitor of DOT1L with cellular activityThis probe is available from Tocris, Sigma and Cayman Chemical. The control may be requested by clicking here. For any inquiries please contact proberequests@thesgc.org.group newOverview Protein methyltransferases (PMTs) play essential roles in epigenetic regulation of gene expression and chromatin dependent signaling via their methylation of histones and other chromatin associated substrates. Mutation or misregulation of PMTs is linked to many diseases, especially cancer, and there is strong interest in this family of proteins as potential drug targets. Most PKMTs contain a conserved SET-domain, with the exception of DOT1L which has a protein fold that more closely resembles PRMTs. DOT1L is also unique in that it is the only PKMT to methylate histone H3 on Lysine 79 (H3K79), a chromatin mark associated with active chromatin and transcriptional elongation. Here we present SGC0946, a potent and selective inhibitor of DOT1L, which potently and selectively kills cells containing an MLL translocation. SGC0946 inhibits DOT1L with an IC50 of 0.3nM in a radioactive enzyme assay and is over 100-fold selective for other HMTs. In addition, SGC0946 potently reduces H3K79 dimethylation with cellular IC50 of 2.6nM in A431 cells, and 8.8nM in MCF10A cells. Properties 1-(3-((((2R,3S,4R,5R)-5-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea Click here to download SDF file Chiral centre is marked by * Physical and chemical properties Molecular weight 653.2 Molecular formula C28H40BrN7O4.HCl IUPAC name 1-(3-((((2R,3S,4R,5R)-5-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea logP 3.51 PSA 120.4 A Storage Stable as solid in the dark at -20°C. SMILES: [H][Cl].CC(C)N(CCCNC(Nc1ccc(cc1)C(C)(C)C)=O)C[C@@H]1[C@H]([C@H]([C@H](n2cc(c3c(N)ncnc23)[Br])O1)O)O InChI: InChI=1S/C28H40BrN7O4.ClH/c1-16(2)35(12-6-11-31-27(39)34-18-9-7-17(8-10-18)28(3,4)5)14-20-22(37)23(38)26(40-20)36-13-19(29)21-24(30)32-15-33-25(21)36;/h7-10,13,15-16,20,22-23,26,37-38H,6,11-12,14H2,1-5H3,(H2,30,32,33)(H2,31,34,39);1H/t20-,22-,23-,26-;/m1./s1 InChIKey: CREBMQZPDVWTPT-DGUBOJIQSA-N Selectivity ProfileSGC0946 selectively inhibits DOT1L Cell-based Assay DataInhibition of H3K79me2 by a series of DOT1L inhibitors in A431 cells (4 day treatment). Co-crystal structures Please wait whilst the interactive viewer is loaded! Main features 1. Overview: Overall binding pose of SGC0946 in the cofactor site of DOT1L. 2. Binding Pocket:Close-up of binding pocket of SGC0946 showing key hydrogen bond interactions with adenosine and urea. 3. Bound to SAM: Catalytically competent conformation of the activation loop bound to SAM. 4. Bound to SGC0946: Catalytically dead conformation of the activation loop to accommodate lipophilic tail of SGC0946. ReferencesCatalytic site remodeling of the DOT1L methyltransferase by selective inhibitors Wenyu Yu, Emma J. Chory, Amy K. Wernimont, Wolfram Tempel, Alex Scopton, Alexander Federation, Jason J. Marineau, Jun Qi, Dalia Barsyte-Lovejoy, Joanna Yi, Richard Marcellus, Roxana E. Iacob, John R. Engen, Erno Wienholds, Fengling Li, Javier Pineda, Guillermina Estiu, Tatiana Shatseva, Taraneh Hajian, Rima Al-awar, John E. Dick, Masoud Vedadi, Peter J. Brown, Cheryl H. Arrowsmith *, James E. Bradner *, Matthieu Schapira *. Nature Communications 3 : 1288doi:10.1038/ncomms2304 (2012)